肿瘤细胞治疗研究
英文原题：Rewiring immunity with in vivo CAR T cell engineering.
我们以转化展望作结，既强调机遇，也指出那些将决定临床实施路径的悬而未决的问题。
离体工程化嵌合抗原受体（CAR）T 细胞疗法已改变某些血液系统恶性肿瘤的治疗，但生产流程复杂、患者可及性有限，制约了其影响范围。体内 CAR-T 细胞工程旨在直接在个体体内生成 CAR-T 细胞，以克服这些限制。本文展望肿瘤领域快速发展的体内 CAR-T 细胞生成研究，概述淋巴细胞靶向原则，讨论药理学特征和生物分布，并评估新出现的安全性问题。最后，我们从转化研究角度展望该领域，重点指出其机遇以及决定临床应用路径的待解问题。
Ex vivo engineered chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of certain hematologic malignancies, yet manufacturing complexities and limited patient accessibility constrain its impact. In vivo CAR T cell engineering seeks to overcome these limitations by generating CAR T cells directly within an individual. This Perspective examines the rapidly evolving field of in vivo CAR T cell generation in oncology, outlines principles of lymphocyte targeting, discusses pharmacology and biodistribution and assesses emerging safety issues. We conclude with a translational outlook, highlighting both the opportunities and the outstanding questions that will define the path to clinical implementation.
MEMBER ACCOUNT
登录成功会直接打开下一页。
